Literature DB >> 29539277

CAR T-Cell Therapy in Large B-Cell Lymphoma.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29539277     DOI： 10.1056/NEJMc1800913

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Immunotherapy in Older Adults with Cancer.

Authors:  Richard Curtis Godby; Douglas B Johnson; Grant R Williams
Journal:  Curr Oncol Rep       Date:  2019-05-07       Impact factor: 5.075

2.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

3.  Considerations for cancer immunotherapy biomarker research during COVID-19.

Authors:  Jennifer W Carlisle; Caroline S Jansen; Mehmet Asim Bilen; Haydn Kissick
Journal:  Endocr Relat Cancer       Date:  2020-09       Impact factor: 5.678

Review 4.  C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.

Authors:  Caron A Jacobson; Marcela V Maus
Journal:  Blood Adv       Date:  2020-11-24

5.  Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro.

Authors:  Klaus G Schmetterer; Katrin Goldhahn; Liesa S Ziegler; Marlene C Gerner; Ralf L J Schmidt; Madeleine Themanns; Eva Zebedin-Brandl; Doris Trapin; Judith Leitner; Winfried F Pickl; Peter Steinberger; Ilse Schwarzinger; Rodrig Marculescu
Journal:  Front Immunol       Date:  2019-07-30       Impact factor: 7.561

Review 6.  CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.

Authors:  Dennis C Harrer; Jan Dörrie; Niels Schaft
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

Review 7.  Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.

Authors:  Xinrong Xiang; Qiao He; Yang Ou; Wen Wang; Yu Wu
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

Review 8.  Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.

Authors:  Jeff Rytlewski; Mohammed M Milhem; Varun Monga
Journal:  Ann Transl Med       Date:  2021-06

Review 9.  Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.

Authors:  Kei Kunimasa; Taichiro Goto
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

Review 10.  Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?

Authors:  Annalisa Chiappella; Jennifer Crombie; Anna Guidetti; Umberto Vitolo; Philippe Armand; Paolo Corradini
Journal:  Hemasphere       Date:  2019-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.